Daré Bioscience (NASDAQ:DARE) Stock Price Crosses Below 200 Day Moving Average – What’s Next?

Daré Bioscience, Inc. (NASDAQ:DARE)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.65 and traded as low as $3.18. Daré Bioscience shares last traded at $3.20, with a volume of 23,719 shares traded.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a research report on Tuesday, December 17th.

Daré Bioscience Stock Performance

The stock has a market capitalization of $27.84 million, a P/E ratio of -5.42 and a beta of 1.27. The stock has a 50-day moving average price of $3.52 and a two-hundred day moving average price of $3.65.

Institutional Investors Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC increased its stake in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the period. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. 6.70% of the stock is currently owned by institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.